Online inquiry

IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1810MR)

This product GTTS-WQ1810MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1810MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4394MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ13681MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RC18
GTTS-WQ11631MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ3691MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ11131MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ4955MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ11939MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ7236MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW